Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15076 - 15100 of 15399 in total
PF-00446687 has been investigated for the treatment of Erectile Dysfunction.
Investigational
Experimental
Matched Iupac: … 7-chloro-5-(cyclohex-1-en-1-yl)-1-methyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one …
Experimental
Illicit
Experimental
Experimental
Experimental
Experimental
Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Withdrawn
Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though no results were reported).
Investigational
Matched Iupac: … -2,3-dihydroxypropanoyl]-1,2,3,6-tetrahydropyridin-4-yl}-3,5-difluorophenyl)-5-[(1,2-oxazol-3-yloxy)methyl
Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
Investigational
Investigational
Displaying drugs 15076 - 15100 of 15399 in total